Criteria to qualify for this study: Drug used in study:
  • Relapsed of refractory multiple myeloma Or relapsed or refractory B-Cell NHL
    After at least 2 prior regimens

HR 59

A Phase Ia/Ib open –label, multicenter study evaluating the safety and pharmacokinetics of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma

Criteria to qualify for this study: Drug used in study:
  • Measurable disease defined as serum M protein >200mg/24 hours, or serum FLC (sFLC) assay: involved FLC level >10mg/dl provided sFLC ratio is abnormal.

MM 95

A Phase 1, First in Man, Multicenter, Open-Label, two part dose escalation and cohort expansion study of Single-Agent GBR 1342 in subjects with previously treated Multiple Myeloma
Criteria to qualify for this study: Drug used in study:
  • Relapsed CAR-T

MM 88 Poseida PBMCS – 101 – 001

Open-Label, Multi-Center, Single Ascending Dose Study to Assess the Safety of P-BMCA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma.

Criteria to qualify for this study: Drug used in study:
  • Relapsed / Refractory
  • 2 part, multicenter, open label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma and multiple myeloma

HR 56 TTI-622-01

A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.

Criteria to qualify for this study: Drug used in study:
  • Received more than 3 lines of therapy including a PI, IMiD and anti-CD-38 mAb or refractory to PI agent and IMiD

M111

A Phase 1 Open First in Human Dose Escalation and expansion study of the immunoproteasome inhibitor M3258 in combination with Dexamethasone in participants with relapsed refractory Multiple Myeloma.

Criteria to qualify for this study: Drug used in study:
  • Relapsed or refractory MM after 3+ lines of therapy.

MM113

A Single-Arm, Open-Label, Phase 1 Study of the safety, efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-715 to evaluate and Anti-BCMA Allogeneic CAR-T Cell Therapy in subjects with relapsed/refractory Multiple Myeloma.

Criteria to qualify for this study: Drug used in study:
  • Relapsed of refractory with measureable disease; newly diagnosis, untreated

MM114

A Phase 1/2 , Multicenter, Open-label, study to determine the recommended dose and regimen, and evaluate the safety and preliminary efficacy efficacy of CC-92480 in combination with standard treatments in subjects with relapsed or refractory (RRMM) and newly diagnosed Multiple Myeloma (NDMM).

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed multiple myeloma with 4-8 cycles of induction and autologous stem cell transplant, archived bone marrow biopsy sample collected before induction or transplant.

MM 109

A randomized study of Daratumumab plus Lenalidomide vs. Lenalidomide alone as maintenance treatment in patients with newly diagnosed Multiple Myeloma who are minimal residual disease positive after frontline Autologous stem cell transplant.

Criteria to qualify for study: Drug used in study:
  • At least 3 prior lines of therapy; ECOG of 1 or 1

MM 100

An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed of refractory Multiple Myeloma.

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed MM; ECOG less than 2

MM 118

A Phase l/ll Study of Human Placental Hematopoietics Stem Cell Derived Natural Killer Cells (CYNK-001) in Multiple Myeloma patients following Autologous Stem Cell Transplant in the Front Line Setting.

Criteria to qualify for study: Drug used in study:
  • ISS Stage 3 Newly diagnosed MM; no more than 3 complete cycles of induction therapy

MM 120

A Phase 1, Open-Label, Multicenter study to evaluate the safety of BB2121 in subjects with High Risk, Newly Diagnosed Multiple Myeloma.

Criteria to qualify for study: Drug used in study:
  • At least 3 prior lines of therapy (including proteasome inhibitor, immune modulatory drug, and an anti-CD38 antibody)

MM 121

A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion study of the safety, tolerability, and Pharmocokinetics of HPN217 in patients with Relapsed/Refractory Multiple Myeloma.